Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3

Conditions

Neuroblastoma 9Ganglioneuroblastoma 3

Interventions

Magnetic Resonance Spectroscopy 5Cyclophosphamide 5dinutuximab 3Topotecan 3Etoposide 3Doxorubicin 3Carboplatin 3Biopsy 3sargramostim 2Vincristine 2Thiotepa 2Stem Cell Transplantation 2Specimen Handling 2Radiation 2Platinum 2Melphalan 2Isotretinoin 2Colony-Stimulating Factors 2Cisplatin 21,2-diaminocyclohexaneplatinum II citrate 2iberdomide 1gallium Ga 68 dotatate 1fludarabine 1Watchful Waiting 1Transurethral Resection of Bladder 1Temozolomide 1Razoxane 1Radiotherapy 1Proton Therapy 1Observation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Ganglioneuroblastoma × dinutuximab × 90 days × Clear all
NCT06172296 2026-06-03

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 3 Recruiting
478 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

NCT03786783 2026-06-02

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 2 Completed
42 enrolled 12 charts
CNS

Ganglioneuroblastoma

NCT07437963 2026-04-15

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

National Cancer Institute (NCI)

Phase 1/2 Not yet recruiting
76 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡